Sector
PharmaceuticalsOpen
₹1,190.8Prev. Close
₹1,190.8Turnover(Lac.)
₹1,648.78Day's High
₹1,204.9Day's Low
₹1,16452 Week's High
₹1,303.952 Week's Low
₹707.15Book Value
₹258.7Face Value
₹2Mkt Cap (₹ Cr.)
23,031.3P/E
31.41EPS
37.91Divi. Yield
0.9221 Jun 2024
12:00 AM
AGM
Announcement Date: 21 Jun, 2024
25 Jul 2024
12:00 AM
Board Meeting
Agenda : Audited Result
9 May 2024
12:00 AM
Dividend
Dividend Amount: 11
Record Date: 15 Jul, 2024
The business stated that the authorised ANDA is therapeutically similar to the reference-listed drug product (RLD) Lastacaft Solution.
The approved Lamotrigine Extended-Release tablets are therapeutic equivalents of GlaxoSmithKline's Lamictal XR, with strengths of 200 mg, 250 mg, and 300 mg.
Alembic Pharmaceuticals has got the final approval from USFDA for Dabigatran Etexilate Capsules, 110 mg.
Alembic has 210 ANDA approvals from the USFDA, including 182 final approvals and 28 tentative clearances.
This certification allows a company to apply for approval of a generic drug before the patents of the brand-name drug expire.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 39.31 | 39.31 | 39.31 | 39.31 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 4,869.6 | 4,374.99 | 5,251.03 | 5,062.5 |
Net Worth | 4,908.91 | 4,414.3 | 5,290.34 | 5,101.81 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 5,051.44 | 4,132.55 | 2,945.26 | 2,985.9 |
yoy growth (%) | 22.23 | 40.31 | -1.36 | -0.76 |
Raw materials | -1,297.91 | -1,045.89 | -892.73 | -886.29 |
As % of sales | 25.69 | 25.3 | 30.31 | 29.68 |
Employee costs | -948.27 | -806.37 | -582.72 | -527.46 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1,416.6 | 1,176.79 | 535.23 | 549.71 |
Depreciation | -152.6 | -135.67 | -101.76 | -82.9 |
Tax paid | -241.21 | -197.39 | -113.25 | -119.08 |
Working capital | -16.69 | 598.87 | 208.77 | -67.37 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 22.23 | 40.31 | -1.36 | -0.76 |
Op profit growth | 30.7 | 90.16 | -0.1 | -35.56 |
EBIT growth | 18.91 | 123.64 | -2.79 | -39.74 |
Net profit growth | 21.24 | 129.72 | -2 | -38.36 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 | 4,605.75 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 | 4,605.75 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 28.31 | 2.74 | 55.74 | 87.29 | 40.36 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,901.95 | 162.71 | 4,52,850.48 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 6,142.25 | 94.94 | 1,57,701.61 | 430 | 0.5 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,595.75 | 32.91 | 1,30,708.75 | 1,055.94 | 0.8 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,497.05 | 77.55 | 1,16,560.45 | 469 | 0.81 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,599.2 | 26.66 | 1,09,845.92 | 1,417.2 | 0.61 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & CEO
Chirayu R Amin
Director (Finance) & CFO
Rajkumar Baheti
Managing Director
Pranav Amin
Managing Director
Shaunak Amin
Independent Director
Archana Hingorani
Independent Director
Ashok Barat
Company Sec. & Compli. Officer
Manisha Saraf
Independent Director
Jai S Diwanji
Independent Director
Manish Kejriwal
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Alembic Pharmaceuticals Ltd
Summary
Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world. The companys state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business. As per the scheme of arrangement, the Pharmaceutical Undertaking of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010. In April 15, 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.In September 20, 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agree
Read More
What is the Alembic Pharmaceuticals Ltd share price today?
The Alembic Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1171.7 today.
What is the Market Cap of Alembic Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alembic Pharmaceuticals Ltd is ₹23031.30 Cr. as of 11 Oct ‘24
What is the PE and PB ratio of Alembic Pharmaceuticals Ltd?
The PE and PB ratios of Alembic Pharmaceuticals Ltd is 31.41 and 4.77 as of 11 Oct ‘24
What is the 52 Week High and Low of Alembic Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Alembic Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Alembic Pharmaceuticals Ltd is ₹707.15 and ₹1303.9 as of 11 Oct ‘24
What is the CAGR of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd's CAGR for 5 Years at 17.13%, 3 Years at 13.24%, 1 Year at 55.26%, 6 Month at 19.83%, 3 Month at 20.89% and 1 Month at -4.25%.
What is the shareholding pattern of Alembic Pharmaceuticals Ltd?
The shareholding pattern of Alembic Pharmaceuticals Ltd is as follows:
Promoters - 69.61 %
Institutions - 19.79 %
Public - 10.60 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
